Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

B.C. man among first Canadians approved for COVID-19 vaccine injury payout
Ross Wightman, who was diagnosed with Guillain-Barré Syndrome last year following a dose of the AstraZeneca COVID-19 vaccine, has been approved for a pain and suffering payout under Canada's Vaccine Injury Support Program. (Source: CBC | Health)
Source: CBC | Health - June 1, 2022 Category: Consumer Health News Tags: News/Canada/British Columbia Source Type: news

Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news

Acute nitrous oxide-induced neuropathy mimicking Guillain-Barr é Syndrome - Qin X, Kang L, Liu X, Jin J, Hu F, Lu W, Deng Y, Chen QY, Dang J.
BACKGROUND AND OBJECTIVE: The early clinical features of nitrous oxide (N(2) O)-induced neuropathy were mimicking that of Guillain-Barr é Syndrome (GBS). We aimed to explore clinical and laboratory characteristics of N(2) O-induced neuropathy in comparison... (Source: SafetyLit)
Source: SafetyLit - May 28, 2022 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Regulatory approval of COVID-19 Vaccine Janssen, MHRA (updated 12th May 2022)
Information for healthcare professionals and the public about the COVID-19 Vaccine Janssen 12 May 2022Updated SPC and PIL: SPC - Under " Special Warnings " section, " Guillain-Barr é syndrome " section updated to include transverse myelitis. PIL - Added info on Neurological disorders - Inflamation of the spinal corrd (transverse myelitis) PIL - Added inflamation of the spinal cord to " Possible side effects " section, under " unknown " heading. 14 February 2022Updated product information for HTML links to Summary of product characteristics and patient information leaflet. The changes are also included in the PDF att...
Source: Current Awareness Service for Health (CASH) - May 12, 2022 Category: Consumer Health News Source Type: news

Johnson & Johnson Updates U.S. COVID-19 Vaccine Fact Sheet
NEW BRUNSWICK, NJ, May 5, 2022 - Our number one priority is the safety and well-being of those who use the Johnson & Johnson COVID-19 vaccine. Johnson & Johnson, in close coordination with the U.S. Food and Drug Administration (FDA), has updated its U.S. COVID-19 Vaccine Fact Sheet to increase awareness about the risk of thrombosis with thrombocytopenia syndrome (TTS), a rare but potentially life-threatening condition. Language about the risk of TTS has been added to the first page of the Fact Sheet to increase its prominence. Following the update to the Fact Sheet, the Johnson & Johnson COVID-19 vaccine is now...
Source: Johnson and Johnson - May 5, 2022 Category: Pharmaceuticals Source Type: news

New Data Confirm Risk of Guillain-Barre With J & J COVID Shot New Data Confirm Risk of Guillain-Barre With J & J COVID Shot
The data support current US guidance that preferentially recommends use of an mRNA COVID-19 vaccine for primary and booster doses.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 3, 2022 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news

Guillain-barre/Miller Fisher Overlap Syndrome After COVID-19 Guillain-barre/Miller Fisher Overlap Syndrome After COVID-19
An acute motor sensory axonal neuropathy is a neurological complication that may result from COVID-19-provoked Guillain-barre syndrome, as seen in this patient.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 28, 2022 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Guillain-Barre Risk After COVID-19 Vaccines Low, Surveillance Data Show
(MedPage Today) -- Risk of Guillain-Barré syndrome after COVID-19 vaccines was low overall, but unusually high after the Johnson & Johnson shot, surveillance data showed. Among 15.1 million doses of COVID-19 vaccines included in the Vaccine... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - April 27, 2022 Category: Infectious Diseases Source Type: news

Risk for Guillain-Barr é Syndrome Up After Ad.26.COV2.S Vaccination
TUESDAY, April 26, 2022 -- The incidence of Guillain-Barré syndrome (GBS) is increased after Ad.26.COV2.S vaccination, but incidence is not increased after mRNA vaccination, according to a study published online April 26 in JAMA Network... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 26, 2022 Category: Pharmaceuticals Source Type: news

Study: Guillain –Barré syndrome risk with COVID-19 vaccines low, but higher with J & J shot
The risk for developing Guillain-Barr é syndrome, a condition that causes severe muscle weakness, after receipt of a COVID-19 vaccine is small, but higher with the Johnson& Johnson shot, according to a study. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 26, 2022 Category: Consumer Health News Source Type: news

Recent Cancer May Increase Risk for Guillain-Barr é Syndrome
FRIDAY, March 4, 2022 -- Recent cancer is associated with an increased risk for subsequent Guillain-Barré syndrome (GBS), according to a study published online March 2 in Neurology. Lotte Sahin Levison, M.D., Ph.D., from Aarhus University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 4, 2022 Category: Pharmaceuticals Source Type: news

Study Shows Nerve Damage In Long Covid Even After Only Mild Covid-19
There have been reports of "long haulers" suffering Guillain-Barr é syndrome, mononeuritis multiplex, brachial plexitis, cranial neuropathies, orthostatic intolerance, and a variety of other neurological issues. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 3, 2022 Category: Pharmaceuticals Authors: Bruce Y. Lee, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Science /science business pharma Source Type: news

Cancer may TRIPLE risk of developing nerve-numbing disorder Guillain-Barré syndrome
Researchers in Denmark, who studied 6million patients, found two per cent of those suffering from the potentially life-threatening condition recently received a cancer diagnosis. (Source: the Mail online | Health)
Source: the Mail online | Health - March 2, 2022 Category: Consumer Health News Source Type: news

Certain cancers may raise risk for Guillain-Barr é syndrome, study finds
People with lymphoma and blood cancers, as well as those who have lung, prostate or breast cancer, may be at higher risk for having new onset Guillain-Barr é syndrome, a study published by the journal Neurology found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 2, 2022 Category: Consumer Health News Source Type: news